sur SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech Reports Significant Growth in 2025
Sartorius Stedim Biotech, a key partner in the biopharmaceutical industry, reported strong growth for the first nine months of 2025. Sales revenue reached €2,195 million, marking a 10.2% increase in constant currencies. This growth was primarily driven by the high-margin consumables sector, which saw consistent improvement across all regions.
The company's underlying EBITDA increased by 21.0% to €683 million, reflecting robust profitability. As a result, the underlying EBITDA margin rose to 31.1%. Despite industry-wide investment hesitancy in bioprocessing equipment, the sector showed signs of stabilization, contributing positively to the overall performance.
Looking ahead, Sartorius Stedim Biotech has refined its full-year guidance to reflect optimistic prospects. The company anticipates sales revenue growth of around 9% and an underlying EBITDA margin of approximately 31%.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SARTORIUS STED BIO